Annovis Bio (ANVS) Stock Overview
A clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ANVS Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Annovis Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.03 |
| 52 Week High | US$10.54 |
| 52 Week Low | US$1.11 |
| Beta | 1.63 |
| 1 Month Change | -14.35% |
| 3 Month Change | -23.40% |
| 1 Year Change | -76.56% |
| 3 Year Change | -82.90% |
| 5 Year Change | -59.40% |
| Change since IPO | -78.83% |
Recent News & Updates
Recent updates
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully
Jun 25
We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate
Dec 06Annovis Bio To Continue Alzheimer's Disease Clinical Trials
Oct 17Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom
Sep 27Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints
Jul 08Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Jun 30Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Shareholder Returns
| ANVS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.7% | 0.4% | -1.5% |
| 1Y | -76.6% | -0.7% | 14.4% |
Return vs Industry: ANVS underperformed the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: ANVS underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| ANVS volatility | |
|---|---|
| ANVS Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANVS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ANVS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 12 | Maria Maccecchini | www.annovisbio.com |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia.
Annovis Bio, Inc. Fundamentals Summary
| ANVS fundamental statistics | |
|---|---|
| Market cap | US$35.27m |
| Earnings (TTM) | -US$30.26m |
| Revenue (TTM) | n/a |
Is ANVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANVS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.26m |
| Earnings | -US$30.26m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANVS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 09:53 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Annovis Bio, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Jason Kolbert | D. Boral Capital LLC. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |